Manchester, NH – PRO Therapeutics (PRO-T), an advanced biotechnology company located in Manchester, NH has appointed Adam Jakus, PhD, as the company’s Chief Operating Officer. Dr. Jakus brings a wealth of experience in the biotechnology sector, particularly in advanced biomaterials and biofabrication approaches, entrepreneurship, operations, and manufacturing. His leadership is expected to significantly enhance PRO-Therapeutics’ mission to deliver transformative musculoskeletal product solutions for physicians and patients.
Dedicated to pioneering innovative musculoskeletal solutions, PRO-T aims to improve patients’ quality of life through development of non-cellular, biologic grafts for soft-tissue repair, which can effectively address the challenges associated with ligament and tendon injuries. The company is actively pursuing products that promise to enhance outcomes in procedures such as rotator cuff and ACL repairs.
Co-founder and Chief Science Officer, Lisa Larkin, Ph.D., shared “Having dedicated my career to musculoskeletal tissue engineering, I am thrilled to bring someone with Dr. Jakus’ experience in both technology and commercialization to help bring our products to patients. With a strong foundation in over $5 million in government funding, this addition to our team positions us to continue our growth.”
Dr. Jakus expressed enthusiasm for his new role, stating, “I am excited to join a team that is at the forefront of biofabrication technology. Building on decades of research by co-founder and inventor, Dr. Lisa Larkin, we are committed to advancing product development and securing capital to ensure that our innovative solutions reach those in need. I look forward to contributing to a company that is poised to make a significant impact in the field of musculoskeletal health and regenerative therapies.”
“It is notable that PRO-T was the first company accepted into the Advanced Regenerative Manufacturing Institute’s (ARMI’s) BioFab Startup Lab,” added Julie Lenzer, PRO-T Board member and ARMI’s Chief Innovation Officer. “This relationship provides resources including access to talent like Dr. Jakus, as well as infrastructure such as labs and regulatory support, to de-risk and thereby accelerate the company’s path to impact. Dr. Jakus’ addition to the team comes at the perfect time in the company’s growth.”
For more information, please direct questions and inquiries to: info@pro-thera.com